Amy W Law

Dr. Amy W Law

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2023 in Vaccine
Verified
Journal Article
Open access
ALAmy W Law
Amy W Law
JJJennifer Judy
Jennifer Judy
JAJessica E. Atwell
Jessica E. Atwell
SWSarah Willis
Sarah Willis
KSKimberly M. Shea
Kimberly M. Shea
Assessment of maternal vaccine coverage is important for understanding and quantifying the impact of currently recommended vaccines as well as modeling the potential impact of future vaccines. However, existing data lack detail regarding uptake according to week of gestational age (wGA). Such granularity is valuable for more accurate estimation of vaccine impact. To summarize contemporary maternal Tdap vaccination uptake, overall, yearly, and by wGA, and maternal influenza vaccination uptake, overall, by influenza observation year, immunization month, and delivery month, in the US. Female patients 18-49 years of age with a pregnancy resulting in a live born infant (i.e., delivery) between 2017 and 2021 were selected from the Optum electronic health records (EHRs) database. Recently published gestational age algorithms were utilized to estimate wGA. Of 1,021,260 deliveries among 886,660 women between 2017-2021, 55.1% had Tdap vaccination during pregnancy; vaccine coverage varied slightly by year (2017: 56.6%; 2018: 55.2%; 2019: 55.2%; 2020: 54.7%; 2021: 52.1%). Most (64.4%) maternal Tdap vaccinations occurred 27-32 wGA; 79.5% occurred during the entire 10-week recommended vaccination window (27-36 wGA). In the evaluation of influenza vaccination uptake (n=798,113 deliveries; 714,841 women), 33.5% of deliveries had influenza vaccination during influenza observation years 2017-2021, most (73.0%) of which occurred during influenza peak activity months (October-January) with approximately one-quarter (27.0%) of vaccinations having occurred during the off-peak months, mostly in September. In this large contemporary analysis of EHR data, uptake of Tdap vaccination during pregnancy was consistent with previously published estimates; notably, most vaccination occurred early in the recommended 27-36 wGA window. Maternal influenza vaccination uptake largely correlated with peak influenza activity months and not gestational age. These study findings may have important implications for estimating the potential uptake and impact of future maternal vaccines.

20 May 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
KBKathleen M. Beusterien
Kathleen M. Beusterien
ALAmy W Law
Amy W Law
MMMartine Maculaitis
Martine Maculaitis
OWOliver Will
Oliver Will
LKLewis Kopenhafer
Lewis Kopenhafer
KSKimberly M. Shea
Kimberly M. Shea
We assessed the impact of respiratory syncytial virus (RSV) preventive characteristics on the intentions of pregnant people and healthcare providers (HCPs) to protect infants with a maternal vaccine or monoclonal antibodies (mAbs). Pregnant people and HCPs who treated pregnant people and/or infants were recruited via convenience sample from a general research panel to complete a cross-sectional, web-based survey, including a discrete choice experiment (DCE) wherein respondents chose between hypothetical RSV preventive profiles varying on five attributes (effectiveness, preventive type [maternal vaccine vs. mAb], injection recipient/timing, type of medical visit required to receive the injection, and duration of protection during RSV season) and a no-preventive option. A best–worst scaling (BWS) exercise was included to explore the impact of additional attributes on preventive preferences. Data were collected between October and November 2022. Attribute-level preference weights and relative importance (RI) were estimated. Overall, 992 pregnant people and 310 HCPs participated. A preventive (vs. none) was chosen 89.2% (pregnant people) and 96.0% (HCPs) of the time (DCE). Effectiveness was most important to preventive choice for pregnant people (RI = 48.0%) and HCPs (RI = 41.7%); all else equal, pregnant people (RI = 5.5%) and HCPs (RI = 7.2%) preferred the maternal vaccine over mAbs, although preventive type had limited influence on choice. Longer protection, protection starting at birth or the beginning of RSV season, and use for both pre-term and full-term babies were ranked highest in importance (BWS). Pregnant people and HCPs strongly preferred a preventive to protect infants against RSV (vs. none), underscoring the need to incorporate RSV preventives into routine care.

29 March 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
ALAmy W Law
Amy W Law
JLJay Lin
Jay Lin
JJJennifer Judy
Jennifer Judy
SPSarah Pugh
Sarah Pugh
ACAlejandro Cane
Alejandro Cane
Background/Objectives: The CDC has recommended immunizations to protect infants during the respiratory syncytial virus (RSV) season, which varies annually and geographically. Seasonal differences in RSV hospitalizations among infants are not well studied. Methods: This retrospective cohort study identified infants < 12 months old hospitalized with RSV from the PINC AI Healthcare Database during the 2018–2023 surveillance years (1 July–30 June). Monthly RSV hospitalizations were stratified by U.S. census division and age group (<3, 3–5, 6–8, 9–11 months). Patient characteristics, healthcare resource utilization (HCRU), and cost were compared between typical in-season months (October–March) and typical off-season months (April–September) for RSV hospitalizations. Results: Among 20,531 hospitalizations for RSV (mean age: 4.1 months, 56.4% male), 22% (n = 4510) were off-season; 83% occurred in June–September across US census divisions. Infants < 3 months accounted for 46% (n = 2054) of off-season hospitalizations. Seasonal patterns were similar across age groups. Off-season hospitalizations were associated with longer hospital length of stay (6.9 vs. 4.9 days) and more supplemental oxygen (59.1% vs. 55.5%), intensive care unit admission (30.1% vs. 26.8%), and mechanical ventilation/airflow usage (20.3% vs. 16.3%). Mean hospitalization costs were 40% higher during off-season ($17,911 vs. $12,757). In the surveillance years before (2018–2020) and after (2022–2023) the COVID-19 pandemic, off-season costs and HCRU were consistently higher than in-season. Conclusions: There is an unmet need among the 1 in 5 infants with off-season RSV hospitalizations, which are associated with higher HCRU and costs. Current recommendations on RSV preventives offer limited protection for infants exposed to RSV outside the typical season.

16 January 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
JHJosé Luis Huerta
José Luis Huerta
RKRobyn Kendall
Robyn Kendall
LILuka Ivkovic
Luka Ivkovic
CMCarlos Andres Molina
Carlos Andres Molina
ALAmy W Law
Amy W Law
DMDiana Mendes
Diana Mendes
Background/Objectives: Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in children. A novel RSVpreF vaccine for use among pregnant women for the prevention of RSV in infants is expected to be licensed in Mexico. Hence, the clinical and economic burden of RSV among infants in Mexico, with and without a year-round RSVpreF maternal vaccination program, was estimated. Methods: A cohort model was developed to project clinical and economic outcomes of RSV from birth to 1 year of age for maternal vaccination and no intervention. Incremental cost-effectiveness ratios were calculated from direct cost outcomes, life years, and quality-adjusted life years (QALYs). The value per dose of the RSVpreF for which the program would be cost-effective was explored. Analyses were conducted from the healthcare system perspective, with direct costs (2024 Mexican Pesos [MXN]) and outcomes discounted at 5% annually; scenario and sensitivity analyses tested the robustness of model settings and inputs. Results: Compared to no intervention, a year-round RSVpreF vaccine administered to 1891 M pregnant women would prevent 15,768 hospitalizations, 5505 emergency department cases, and 5505 physician office visits annually, averting MXN 1754 M in direct medical costs with an increase of 3402 life years or 3666 QALYs. The RSVpreF vaccine would be cost-saving up to MXN 1301/dose and cost-effective up to MXN 2105–MXN 3715/dose under an assumed cost-effectiveness threshold range of 1–3× the gross domestic product (GDP) per capita (MXN 247,310) per QALY gained. Conclusions: Year-round RSVpreF maternal vaccination would substantially reduce RSV’s clinical and economic burden among infants in Mexico and likely be a cost-effective program.

5 March 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
DMDiana Mendes
Diana Mendes
MKMalvin Kang
Malvin Kang
ALAmy W Law
Amy W Law
Background/Objectives: Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infections in infants/newborns, sometimes requiring hospitalisation. Two immunisation options are approved in Europe: maternal vaccination and infant immunisation. Success of the immunisation programme depends on uptake—however, understanding of women’s immunisation preferences remains limited. This study evaluated women’s knowledge of RSV, RSV immunisation intentions, and factors influencing immunisation decisions in Finland, France, Germany, Italy, Spain, and the UK. Methods: A cross-sectional survey was conducted between November and December 2024 with 740 women across the selected countries. Participants included women who were pregnant, trying to conceive, or previously pregnant within the year prior to survey. Participants were asked about their knowledge, intentions, and preferences regarding RSV immunisation. Results: Familiarity with RSV was lower than that for COVID-19 and influenza (45% vs. 86% and 85%). Among those pregnant or trying to conceive, 68% reported they were likely to initiate an RSV immunisation discussion with a healthcare provider and 21% reported they were unlikely to do so. The majority (76%) also reported they were likely to accept RSV vaccination if recommended by a healthcare provider. Overall, 52% preferred maternal vaccination over infant immunisation. Among the 82% of women who would consider RSV immunisation and had a preference for immunisation method, 68% favoured maternal vaccination. Conclusions: RSV immunisation acceptance among European women is high and a majority prefer maternal vaccination over infant immunisation. This indicates potential for RSV immunisation to achieve high uptake when women have access to immunisation methods aligned with their preferences.

1 June 2026 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
AAAhuva Averin
Ahuva Averin
ALAmy W Law
Amy W Law
MAMark Atwood
Mark Atwood
EQErin Quinn
Erin Quinn
DWDerek Weycker
Derek Weycker
Lower respiratory tract illness (LRTI) due to respiratory syncytial virus (RSV; RSV-LRTI) is relatively common in children aged <2 y.1,2 Younger infants, those born prematurely, and those with unde...